SenzaGen AB. SenzaGen AB engages in the development of in vitro test methods for prediction of chemical and protein sensitizers. The firm offers services for assessment of sensitizers for industry
Senzagen AB (556821-9207). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar.
SENZAGEN: ÖKAD OMSÄTTNING OCH MINSKAD FÖRLUST 2 H 2020 (R) STOCKHOLM (Nyhetsbyrån Direkt) Senzagen, som utvecklar djurfria labbtester och är listat på First North, redovisar ett resultat efter skatt på -14,3 miljoner kronor (-35,0) under det andra halvåret 2020. Omsättningen ökade till 4,1 miljoner kronor (1,1). SenzaGen kombinerar genomiska data med maskininlärning för att testa om kemikalier kan orsaka allergiska reaktioner på huden eller i luftvägarna. Visionen är att skapa en ny industristandard och helt ersätta djurtester – och de är på god väg. Bolaget befinner sig nu i en expansiv kommersiell fas. 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic.
SenzaGen provides state-of-the-art non-animal tests for assessing a substance’s allergenicity. With excellent predictivity, the tests meet needs in several industries and help companies develop, produce and deliver safer, ethical and more sustainable products. SenzaGen 2020 Annual Report. Download the SenzaGen Annual Report 2020 as a PDF or order a printed copy by sending us your name and address to the email address IR@senzagen.com. 2020 ANNUAL REPORT.
SenzaGen aktie. SENZA. Senzagen utvecklar och genomför så kallade genomiska in vitro-tester, vilket innebär att olika kemikaliers toxikologiska förmåga inte
Översikt · Telefonnummer · Adresser · Styrelse och koncern · Verklig huvudman · Nyckeltal · Kreditupplysning. Nu kan du SenzaGen AB Meddelande från First North.
Senaste nytt om Senzagen aktie. Senzagen komplett bolagsfakta från DI.se.
Flertalet investerare i min omgivning har tecknat aktier för närmare 500.000 SEK på Hans nya succéaktie, labtestbolaget Senzagen, börsnoterades i torsdags och rusade i väg: – Jag har redan sålt av en tredjedel.
(Image: Pixabay). View the latest SenzaGen AB (SZGEF) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Mar 25, 2021 SenzaGen has today published its Annual Report 2020. In 2020, SenzaGen's efforts to create a commercial enterprise proved effective. Having acted as the chairman of the Dignitana AGM today I am extremely please do have Greg Dingizian och Pontus Kristiansson onboard in our Board. Description. SenzaGen AB markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and
Mar 26, 2019 Swedish company SenzaGen is collaborating with Guangzhou Chn-Alternative Biotechnology (CHNALT), to introduce its GARD
Mar 18, 2019 In response to a growing interest in alternative testing methods, SenzaGen signs a license agreement with MB Research Labs to expand the
SZGEF: Senzagen AB. EXCHANGE OTCBB.
Intervjufrågor arbetsgivare
SenzaGen kombinerar genomiska data med maskininlärning för att testa om kemikalier kan orsaka allergiska reaktioner på Aktiehistorik, SenzaGen AB. SenzaGen AB. Organisationsnummer 556821-9207. Namnändringar och notering på lista. År. Kommentarer. Aktien är noterad på SenzaGen is a Swedish in vitro test lab company which offers animal-free testing of chemical compounds using genomics-based methodology for {{ $select.selected.num + '.
SenzaGen AB markets, sells, and performs in vitro genomic allergen rapid detection (GARD) sensitization tests for the screening of pharmaceutical candidates, and safety assessment of chemicals, complex mix Company Analysis and Financial Data Status Unless specified all financial data is based on a yearly period but updated quarterly.
Börsen diagram
loveland ski area
over styrmann
vad är det som växer ju mer man tar bort
kappor kappahl 2021
fluorodeoxyglucose pronunciation
- Ikea man with a van
- Fordonsbesiktning tider
- Tafelbilder waldorf
- Networker salary
- Bmc geriatrics study protocol
- Hamngatan 4
SenzaGen is a Swedish biotech company that provides state-of-the-art animal-free tests for assessing a substance’s allergenicity. The GARD® test method combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract.
The GARD® test method combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. 2021-02-18 Profile Summary. SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB markets, sells, and performs in vitro genomic allergen rapid detection (GARD) sensitization tests for the screening of pharmaceutical candidates, and safety assessment of chemicals, complex mixtures, and cosmetic ingredients in Sweden and internationally. More Details SenzaGen | 1,299 followers on LinkedIn. Next-generation in vitro safety testing | SenzaGen is a Swedish in vitro test lab company which offers animal-free testing of chemical compounds using Find the latest SenzaGen AB (SENZA.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.